Two different families robbed of loved ones by malignant mesothelioma have chosen documentaries as the best way to educate the public about the rare and deadly disease, and both of their films are about to be released: one in the United States and one in London. In London, an international audience viewed the premiere of the film Breathless, while in the United States a film called Dirt Laundry has already made its way through numerous film festivals, and is now being released to audiences around the country. read more
Month: October 2018
In the face of alarming new statistics regarding rising asbestos imports into the United States, mesothelioma victims and health and safety advocates are sounding an alarm, warning of the growing risk of asbestos-related diseases. The outcry follows the release of new data from both the Department of Commerce and the U.S. International Trade commission which reveals a 2000 percent increase in the asbestos imports between July and August of 2018. read more
Victims of asbestos exposure who are diagnosed with malignant mesothelioma are often overwhelmed by their diagnosis and its impact. Depending upon their age, their overall health, the type of mesothelioma they’ve been diagnosed with and how far advanced the disease stage is, they may be told that they have an extremely short period of time in which to settle their affairs. For many in this situation, the best decision is to seek a fair settlement with the companies that are responsible in order to make sure that their medical bills will be taken care of and that they can be assured that their families will have a measure of financial security. Such was the case for a man in the United Kingdom who was exposed through his work at Beldam Asbestos Company Limited. read more
When it comes to mesothelioma, statistical accuracy is essential to making sure that the proper resources are allocated for prevention, treatment, and more. That’s why there is a rising level of concern over what is happening with Quebec’s health ministry: in response to a newspaper inquiry, they released numbers on mesothelioma incidence for the first time in 7 years, and the numbers that they provided are very much in question. read more
When 83-year-old Joan Morris of Essex in the United Kingdom was diagnosed with malignant mesothelioma, her family was both devastated and confused. The rare and fatal form of cancer is cause by exposure to asbestos, and they were not aware of any such exposure she might have had in her life. The illness moved quickly: she began feeling ill in June of 2016, was diagnosed in November, and by March she was gone. Now the family is seeking justice, trying to determine whether her death was a result of years of washing asbestos from her first husband’s work clothing in the years between the mid-1960s and 1970s. read more
While the general population is aware that asbestos is bad, and may even assume that it was banned long ago in the United States, those whose lives have been affected by malignant mesothelioma know all-too well that it is still in use and in place in America’s industries and its infrastructure. With the passage of a law reforming and strengthening the Toxic Substances Control Act in 2016, health and environmental advocates had hoped that change was finally coming and that the substance’s use in the United States would soon come to an end, but the Trump administration has reversed course. In response, six Non-Governmental Organizations (NGOs) have adopted a new strategy: they have submitted a petition to the United States Environmental Protection Agency, requesting that currently existing exemptions to the way that asbestos is treated be dropped.
Mesothelioma researchers attending last week’s International Association for the Study of Lung Cancer (ASLC) 19th World Conference on Lung Cancer attended the gathering with high hopes for breakthroughs in fighting the challenging disease, and they did not leave disappointed. Among the most promising news that the group heard was of groundbreaking results achieved by Aldeyra Therapeutics, Inc. in a Phase 1/2 clinical trial of their drug ADX-1612 (ganetespib).